广州派诺生物技术

Painuo Bio is a clinical-stage biotechnology company headquartered in Guangzhou, China, dedicated to the research and development of innovative vaccines for infectious diseases. The company utilizes two core technology pillars: a proprietary Virus-Like Particle (VLP) platform and an advanced mRNA delivery system. Its pipeline targets high-burden pathogens including SARS-CoV-2, respiratory syncytial virus (RSV), and the varicella-zoster virus. Painuo Bio distinguishes itself through structure-based vaccine design and integrated manufacturing capabilities designed for rapid response to emerging public health threats. The company has successfully advanced its lead COVID-19 vaccine candidate into mid-stage clinical trials and continues to expand its portfolio into chronic infectious diseases and oncology.